Donald Trump has rescinded an executive order from President Joe Biden that sought to lower the price of drugs.

Upon his return to the United States Presidency, Donald Trump signed a number of executive orders that will not have an immediate impact, but will take effect in the coming weeks.

On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.

Trump rescinded Executive Order 14087, "Lowering Prescription Drug Costs for Americans," which directed Medicare and Medicaid agencies to research and implement models for lowering the costs of prescription drugs. Separate provisions in the Inflation Reduction Act of 2022 also aimed at lower prescription drug costs are still in effect.

The White House on Friday said Novo Nordisk’s weight-loss drugs Wegovy and Ozempic were among the 15 medications picked for a round of price negotiations with Medicare. The companies do not have to negotiate, but if they don’t, they face fines or the possible end of Medicare reimbursements.

The Centers for Medicare & Medicaid Services announced 15 new drugs it wants to lower the cost for, including popular, but expensive weight-loss drugs.

Trump’s early health orders signal plans to reverse Biden policies on drug prices and Medicaid. Experts predict more uninsured but await further action.

The Trump administration came into office earlier this week with a promise of cutting down on government spending and driving greater efficiency, but a new poll from KFF shows voters largely support continued spending on Medicare and Medicaid.

Biden spent like no president in history, and, with a sleight of hand, by taking hundreds of billions out of Medicare and spending it on green energy subsidies.

President Donald Trump began his second administration with a blitz of policy actions to reorient U.S. government priorities.

The hugely popular medications Ozempic and Wegovy​, used for diabetes and weight loss, will be included in the next round of talks to negotiate lower Medicare drug prices.

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.